For the first time, the concentration of MCC950 was optimized for vitreous injection, and the effect of MCC950 treatment on vascular injury in the retina of T2DM rats was systematically evaluated by up-regulating the NEK7 molecular axis (ROS-NEK7-NLRP3), revealing that the ROS activates the NLRP3 inflammasome, providing a theoretical basis for precise anti-inflammatory treatment. This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.